Navigation Links
First CyberKnife System in Rhode Island Installed
Date:7/22/2009

SUNNYVALE, Calif., July 22 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Radiosurgery Center of Rhode Island, LLC, installed a CyberKnife(R) Robotic Radiosurgery System within Rhode Island Hospital in Providence, marking the first CyberKnife System in Rhode Island.

"This new technology will allow us to provide the most targeted treatment for our cancer patients," said David Wazer, M.D., medical director of the Radiosurgery Center of Rhode Island, LLC. "CyberKnife's non-invasive design provides maximum benefit for the patient through focused radiation while also providing a shorter radiation cycle and a more comfortable experience with fewer side effects that affect quality of life."

CyberKnife radiosurgery offers a non-invasive treatment for cancerous and non-cancerous tumors. By incorporating robotic mobility and the ability to image throughout the treatment, the CyberKnife System delivers high-doses of radiation to destroy tumors and minimize damage to surrounding healthy tissue. Treatments are completed on an outpatient basis in one to five sessions and patients can typically resume their normal activities immediately following treatment.

Radiosurgery Center of Rhode Island, LLC, is a partnership of Rhode Island Hospital and 21st Century Oncology. For more information on this center, please visit www.cyberkniferi.com

* Figure includes the U.S. Territory of Puerto Rico.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 164 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. John L. LeRoy First Atlanta Plastic Surgeon to Perform Newly Approved Dysport Wrinkle Remover Injections for Facial Rejuvenation
2. Red Cross Leader Describes First-Year Triumphs, Challenges
3. First national study to examine rock climbing-related injuries
4. Misonix Receives First Award for Forensic Equipment in China
5. First Anniversary of New War on Cancer Marks Many Advances
6. RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer
7. STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call
8. ATS Medical Announces First Use of the New ATS CryoMaze 10-S Probe
9. National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company
10. Keep Up With Checkups Puts Prevention First
11. Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... protection services and financial consultations to communities throughout the greater DC region, is ... with the goal of rescuing local animals and training them to be companions ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an Indiana-based firm ... in support of Campagna Academy in a charity drive to provide for at-risk children ... of Indiana,” Campagna Academy is a nonprofit organization that has offered critical programs to ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has ... imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, ... and monitoring solutions, announced today the launch of a redesigned corporate website, ... and aesthetic, fully responsive design, and an enhanced search directory for businesses and ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Three Tru-D SmartUVC robots have arrived at Brian ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing ... services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army ... "Although the BAACH has a very low infection ...
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
(Date:7/26/2017)... 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) today ... evaluating Altemia TM , an oral therapy for pediatric ... Disease (SCD). The SCOT Trial, is a double-blind, placebo-controlled, ... of Altemia TM in pediatric patients aged 5-17 ... 125274. "The completion ...
Breaking Medicine Technology: